MLYSMineralys Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Mineralys Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MLYSThis | $2.5B#7 | — | 4.5x#8 | — | — | 13.0%#3 | — | -28.1%#9 | -41.3%#7 | — | -24.1%#15 | — |
| ARQT | $3.1B#2 | 111.4x#3 | 14.0x#14 | 8.2x#4 | 91.3%#3 | 88.5%#1 | -3.3%#3 | -7.3%#4 | -4.1%#3 | — | 43.0%#7 | — |
| MBX | $3.1B#1 | — | 7.5x#12 | — | — | -40.5%#11 | — | -21.2%#8 | — | — | 542.9%#2 | — |
| PGEN | $2.8B#3 | — | 63.5x#16 | 285.6x#10 | 146.7%#2 | -98.6%#14 | -1141.1%#10 | -575.1%#16 | -91.2%#11 | — | 102.8%#6 | — |
| IMNM | $2.7B#4 | — | 5.2x#9 | 394.5x#11 | -23.2%#10 | 27.5%#2 | -3228.8%#11 | -40.4%#11 | -72.8%#10 | — | 168.6%#5 | — |
| IRON | $2.7B#5 | — | 4.1x#6 | — | — | -94.0%#12 | — | -32.9%#10 | -39.0%#6 | — | 13.5%#12 | — |
| NRIX | $2.7B#6 | — | 6.6x#11 | 31.6x#5 | 54.0%#5 | -36.6%#8 | -340.2%#7 | -65.7%#14 | — | — | 198.1%#3 | — |
| SUPN | $2.5B#8 | — | 2.4x#2 | 3.5x#3 | 8.6%#7 | -152.2%#16 | -8.7%#4 | -3.7%#3 | -5.0%#4 | — | -4.0%#13 | — |
| VRDN | $2.5B#9 | — | 3.7x#5 | 34.9x#6 | 23359.9%#1 | -26.9%#7 | -512.9%#8 | -51.7%#13 | -54.5%#8 | — | 17.3%#11 | — |
| HRMY | $2.5B#10 | 13.7x#2 | 2.5x#3 | 2.8x#2 | 21.5%#6 | 9.1%#5 | 24.0%#2 | 15.9%#1 | 25.5%#1 | 4#1 | 32.2%#10 | — |
| VERA | $2.4B#11 | — | 6.0x#10 | — | — | -96.9%#13 | — | -73.5%#15 | -72.7%#9 | — | 37.2%#8 | — |
| NKTR | $2.4B#12 | — | 2.6x#4 | 42.9x#7 | -43.9%#11 | -37.8%#10 | -253.7%#6 | -18.2%#5 | -14.0%#5 | — | 35.7%#9 | — |
| SLS | $2.3B#13 | — | 16.8x#15 | — | -100.0%#12 | 13.0%#4 | — | -19.5%#7 | — | — | 576.7%#1 | — |
| OCUL | $2.2B#15 | — | 4.3x#7 | 42.9x#8 | -18.5%#9 | -37.4%#9 | -519.8%#9 | -51.1%#12 | — | — | -16.4%#14 | — |
| PVLA | $2.2B#14 | — | 10.3x#13 | 52.3x#9 | 65.3%#4 | -139.3%#15 | -90.2%#5 | -19.2%#6 | — | — | 174.6%#4 | — |
| PBH | $2.2B#16 | 13.0x#1 | 1.1x#1 | 2.0x#1 | -4.3%#8 | -11.3%#6 | 28.4%#1 | 9.9%#2 | 5.9%#2 | 4#1 | -27.4%#16 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice